Jhunjhunwala-backed Rare Enterprises holds 6-month lock-in post Concord Biotech listing
Concord Biotech's financial landscape has undergone notable shifts, with operational margins stabilising around 40-42% in 2023.
Source: moneycontrol.com
Stay updated with breaking news from Lalit Sethi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Concord Biotech's financial landscape has undergone notable shifts, with operational margins stabilising around 40-42% in 2023.
Concord Biotech IPO | The issue comprises only an offer for sale (OFS) by Helix Investment Holdings Pte Limited, which is backed by Quadria Capital Fund LP, a healthcare-focused private equity fund in Asia.
The COVID-19 learning gap has hit students at every level.